COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,252 Articles (22,733 medRxiv, 8,519 bioRxiv)

Most recent first Previous |  Page 662: Articles 6611-6620  | Next

Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine.
Raw, R., Rees, J., Chadwick, D. R.
10.1101/2022.08.19.22278986 — Posted: 2022-08-22
SARS-CoV-2 IgM and IgG serology and clinical outcomes in COVID-19 patients
S, M., Kumar, P., Panda, P. K., Jain, V., Raina, R., Saha, S., S, V., Omar, B. J.
10.1101/2022.08.21.22279044 — Posted: 2022-08-22
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in admitted patients at a tertiary referral centre in North India
Ray, A., Singh, K., Mehdi, F., Chattopadhyay, S., Jadon, R. S., Nischal, N., Soneja, M., Sethi, P., Meena, V. P., Trikha, A., Batra, G., Wig, N.
10.1101/2022.08.19.22278876 — Posted: 2022-08-22
Proteomics Investigation of Diverse Serological Patterns in COVID-19
Liang, X., Sun, R., Wang, J., Zhou, K., Li, J., Chen, S., Lyu, M., Li, S., Xue, Z., Shi, Y., Xie, Y., Zhang, Q., Yi, X., Pan, J., Wang, D., Xu, J., Zhu, H., Zhu, G., Zhu, J., Zhu, Y., Zheng, Y., Shen, B., Guo, T.
10.1101/2022.08.21.22278967 — Posted: 2022-08-22
Association between Blood N-3 Fatty Acid Levels and Risk for COVID-19 in the UK biobank
Harris, W. S., Tintle, N. L., Sathyanarayanan, S. P., Westra, J.
10.1101/2022.08.19.22278992 — Posted: 2022-08-22
LONGITUDINAL CLUSTER ANALYSIS OF HEMODIALYSIS PATIENTS WITH COVID-19 IN THE PRE-VACCINATION ERA
Esposito, P., Garbarino, S., Fenoglio, D., Cama, I., Cipriani, L., Campi, C., Parodi, A., Vigo, T., Franciotta, D., Altosole, T., Grosjean, F., Viazzi, F., Filaci, G., Piana, M.
10.1101/2022.08.20.22279014 — Posted: 2022-08-22
LENZILUMAB OUTCOMES ACCORDING TO RACE OF COVID-19 PARTICIPANTS IN THE LIVE-AIR PHASE 3 TRIAL
Marconi, V., Kilcoyne, A., Cerasoli, F., Polk, C., Lewis, M., Burger, C., Jordan, E., Durrant, C., Chappell, D., Temesgen, Z.
10.1101/2022.08.18.22278867 — Posted: 2022-08-21
A randomized, double-blind, Phase 1 study of IN-006, an inhaled antibody treatment for COVID-19
Moench, T. R., Botta, L., Farrer, B., Lickliter, J. D., Kang, H., Park, Y., Kim, C., Hoke, M., Brennan, M., McSweeney, M. D., Richardson, Z., Whelan, J. B., Cho, J. M., Lee, S. Y., Faurot, F., Hutchins, J., Lai, S. K.
10.1101/2022.08.17.22278748 — Posted: 2022-08-21
Effectiveness of fourth dose COVID-19 vaccine against the Omicron variant compared to no vaccination
Zeng, J., Szanyi, J., Blakely, T.
10.1101/2022.08.17.22278807 — Posted: 2022-08-21
Cohort monitoring of 29 Adverse Events of Special Interest prior to and after COVID-19 vaccination in four large European electronic healthcare data sources
Sturkenboom, M. C., Messina, D., Paoletti, O., Burgos Gonzalez, A., Garcia-Poza, P., Llorente- Garcia, A., Huerta, C., Martin-Perez, M., Martin, I., Overbeek, J., Padros-Goossens, M., Souverein, P., Swart-Polinder, K., Klungel, O., Gini, R.
10.1101/2022.08.17.22278894 — Posted: 2022-08-20

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).